Neonatal Seizures – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Neonatal Seizures represent the most distinctive frequent manifestations of neurological dysfunction in the neonatal period. Neonatal seizures are clinically described as abnormal, stereotyped and paroxysmal dysfunctions in the central nervous system (CNS) occurring within the first 28 days after birth in full-term infants or before 44 weeks of gestational age in preterm infants. It is a relatively common occurrence in neonates with a heterogeneous etiology, and most infants are acutely symptomatic. The etiologies are different in term and preterm infants. Hypoxic-ischemic encephalopathy (HIE), stroke, cerebral malformations and metabolic disorders are major causes of seizures in term infants. Some significant causes in preterm infants are intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL) and infections. Neonatal seizures are often the first clinical sign of underlying neurological dysfunction, with the most common causes being hypoxic-ischemic encephalopathy (HIE), perinatal stroke and intracranial haemorrhage. Due to the frequency of these conditions and the relative excitability of the newborn brain, the neonatal period, in particular the first week of life, is the most vulnerable period for the development of seizures.
• The incidence of neonatal seizures varies between 1 to 5 cases per 1000 live births, with significantly higher rates in premature infants ranging from 55 to 95 per 1000 live births.

Thelansis’s “Neonatal Seizures Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neonatal Seizures treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Neonatal Seizures across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Neonatal Seizures Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Neonatal Seizures – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Neonatal Seizures, Neonatal Seizures market outlook, Neonatal Seizures competitive landscape, Neonatal Seizures market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)